Advancements in Targeted Symptom Mitigation
The oncology landscape in 2026 has transitioned toward a model where patient quality of life is viewed as equally significant to tumor response. Oncology supportive therapies are now leveraging proteomic profiling to identify specific inflammatory markers that precede the onset of common treatment-related toxicities. This proactive approach allows for...
Spanish 
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt